Company News - Certis Oncology

<!doctype html> <html lang="en"> <head> <meta charset="utf-8" /> <title>Company News - Certis Oncology</title> <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no" /> <link rel="stylesheet" media="all" href="/wp-content/themes/certis/dist/css/style.css?v2"/>  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-K5GS2LR');</script> <meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' />  <link rel="canonical" href="https://www.certisoncology.com/about-us/news/" /> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="website" /> <meta property="og:title" content="News Archive" /> <meta property="og:url" content="https://www.certisoncology.com/about-us/news/" /> <meta property="og:site_name" content="Certis Oncology" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="@CertisOncology" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"CollectionPage","@id":"https://www.certisoncology.com/about-us/news/","url":"https://www.certisoncology.com/about-us/news/","name":"Company News - Certis Oncology","isPartOf":{"@id":"https://www.certisoncology.com/#website"},"breadcrumb":{"@id":"https://www.certisoncology.com/about-us/news/#breadcrumb"},"inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https://www.certisoncology.com/about-us/news/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.certisoncology.com/"},{"@type":"ListItem","position":2,"name":"News"}]},{"@type":"WebSite","@id":"https://www.certisoncology.com/#website","url":"https://www.certisoncology.com/","name":"Certis Oncology","description":"","publisher":{"@id":"https://www.certisoncology.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://www.certisoncology.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://www.certisoncology.com/#organization","name":"Certis Oncology","url":"https://www.certisoncology.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://www.certisoncology.com/#/schema/logo/image/","url":"https://www.certisoncology.com/wp-content/uploads/certis-color.svg","contentUrl":"https://www.certisoncology.com/wp-content/uploads/certis-color.svg","width":1,"height":1,"caption":"Certis Oncology"},"image":{"@id":"https://www.certisoncology.com/#/schema/logo/image/"},"sameAs":["https://www.facebook.com/CertisOncology/","https://x.com/CertisOncology","https://www.linkedin.com/company/certis-oncology","https://www.facebook.com/CertisOncology","https://www.instagram.com/certis_oncology","https://www.youtube.com/channel/UCeX4_jh3RlNKxQxZ89_utjg","https://www.certisoncology.com/for-drug-developers/cancer-model-database-request/"]}]}</script>  <style id='classic-theme-styles-inline-css' type='text/css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css' type='text/css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel="https://api.w.org/" href="https://www.certisoncology.com/wp-json/" /></head> <body> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K5GS2LR" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <div class="app" post="7543" :browser="browser" :style="style" v-cloak> <navigation :items="{"featured":{"image":{"ID":5534,"id":5534,"title":"CTA_KRAS-CertiScreen-824x424","filename":"CTA_KRAS-CertiScreen-824x424-1.jpg","filesize":49609,"url":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1.jpg","link":"https:\/\/www.certisoncology.com\/observational-clinical-research-study-testing-kras-targeting-therapies\/cta_kras-certiscreen-824x424\/","alt":"","author":"6","description":"","caption":"","name":"cta_kras-certiscreen-824x424","status":"inherit","uploaded_to":5651,"date":"2023-08-24 19:54:06","modified":"2023-10-03 19:51:30","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.certisoncology.com\/wp-includes\/images\/media\/default.png","width":824,"height":424,"sizes":{"thumbnail":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-720x370.jpg","medium-width":300,"medium-height":154,"medium_large":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-768x395.jpg","medium_large-width":768,"medium_large-height":395,"large":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1.jpg","large-width":824,"large-height":424,"1536x1536":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1.jpg","1536x1536-width":824,"1536x1536-height":424,"2048x2048":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1.jpg","2048x2048-width":824,"2048x2048-height":424,"small":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-540x278.jpg","small-width":540,"small-height":278,"square-sm":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-540x424.jpg","square-sm-width":540,"square-sm-height":424,"square-md":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg","square-md-width":720,"square-md-height":424,"portrait":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1-640x424.jpg","portrait-width":640,"portrait-height":424,"landscape":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/CTA_KRAS-CertiScreen-824x424-1.jpg","landscape-width":824,"landscape-height":424}},"title":"VALIDATE YOUR KRAS-TARGETING STRATEGY ","content":"Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies.<\/p>\n","link":{"title":"Learn More","url":"https:\/\/www.certisoncology.com\/kras-targeted-oncology-drug-development\/","target":""}},"login":"https:\/\/oncointel.certisoncology.com","navigation":[{"ID":6826,"post_author":"2","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-02-15 16:53:06","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"6826","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=6826","menu_order":1,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":6826,"menu_item_parent":"0","object_id":"5","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/","title":"Home","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5867,"post_author":"1","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"Drug Developers","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"drug-developers","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5867","menu_order":2,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5867,"menu_item_parent":"0","object_id":"5867","object":"custom","type":"custom","type_label":"Custom Link","title":"Drug Developers","url":"#","target":"","attr_title":"","description":"","classes":[""],"xfn":"","children":[{"ID":5872,"post_author":"1","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"CertisAI\u2122\ufe0f","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-ai","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5872","menu_order":3,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5872,"menu_item_parent":"5867","object_id":"5060","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/","title":"CertisAI\u2122\ufe0f","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5930,"post_author":"2","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 17:36:22","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5930","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5930","menu_order":4,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5930,"menu_item_parent":"5867","object_id":"221","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/cancer-models-preclinical-studies\/","title":"Cancer Models","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5873,"post_author":"1","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"Custom Models","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"custom-models","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5873","menu_order":5,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5873,"menu_item_parent":"5867","object_id":"137","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/custom-model-development\/","title":"Custom Models","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5932,"post_author":"2","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 17:36:22","post_content":"","post_title":"In Vitro\/Ex Vivo","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"in-vitro-ex-vivo","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5932","menu_order":6,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5932,"menu_item_parent":"5867","object_id":"5912","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/in-vitro-ex-vivo-pharmacology\/","title":"In Vitro\/Ex Vivo","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5933,"post_author":"2","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 17:36:22","post_content":"","post_title":"In Vivo","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"in-vivo","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5933","menu_order":7,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5933,"menu_item_parent":"5867","object_id":"5914","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/in-vivo-pharmacology\/","title":"In Vivo","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5934,"post_author":"2","post_date":"2024-04-09 20:02:43","post_date_gmt":"2024-01-13 17:36:22","post_content":"","post_title":"Imaging\/Endpoints","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"imaging-endpoint","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:43","post_modified_gmt":"2024-04-09 20:02:43","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5934","menu_order":8,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5934,"menu_item_parent":"5867","object_id":"5916","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/imaging-endpoint-analysis\/","title":"Imaging\/Endpoints","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5935,"post_author":"2","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 17:36:22","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5935","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":28,"guid":"https:\/\/www.certisoncology.com\/?p=5935","menu_order":9,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5935,"menu_item_parent":"5867","object_id":"5918","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-drug-developers\/immuno-oncology\/","title":"Immuno-Oncology","target":"","attr_title":"","description":"","classes":[""],"xfn":""}]},{"ID":5868,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"Oncologists","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"oncologists","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5868","menu_order":10,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5868,"menu_item_parent":"0","object_id":"5868","object":"custom","type":"custom","type_label":"Custom Link","title":"Oncologists","url":"#","target":"","attr_title":"","description":"","classes":[""],"xfn":"","children":[{"ID":5937,"post_author":"2","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 17:42:17","post_content":"","post_title":"Order YourPDX\u00ae<\/sup>","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5937","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":389,"guid":"https:\/\/www.certisoncology.com\/?p=5937","menu_order":11,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5937,"menu_item_parent":"5868","object_id":"26","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-oncologists\/order-yourpdx\/","title":"Order YourPDX\u00ae<\/sup>","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5938,"post_author":"2","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 17:42:17","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5938","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":389,"guid":"https:\/\/www.certisoncology.com\/?p=5938","menu_order":12,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5938,"menu_item_parent":"5868","object_id":"5923","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-oncologists\/clinical-research\/","title":"Clinical Research","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5876,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5876","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":389,"guid":"https:\/\/www.certisoncology.com\/?p=5876","menu_order":13,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5876,"menu_item_parent":"5868","object_id":"215","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/for-oncologists\/patient-education\/","title":"Patient Education","target":"","attr_title":"","description":"","classes":[""],"xfn":""}]},{"ID":5869,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"About","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"about","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5869","menu_order":14,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5869,"menu_item_parent":"0","object_id":"5869","object":"custom","type":"custom","type_label":"Custom Link","title":"About","url":"#","target":"","attr_title":"","description":"","classes":[""],"xfn":"","children":[{"ID":5882,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5882","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/?p=5882","menu_order":15,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5882,"menu_item_parent":"5869","object_id":"124","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/mission-vision-values\/","title":"Mission, Vision & Values","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5883,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"team","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/?p=5883","menu_order":16,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5883,"menu_item_parent":"5869","object_id":"126","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/our-team\/","title":"Team","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5884,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5884","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/?p=5884","menu_order":17,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5884,"menu_item_parent":"5869","object_id":"4361","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/our-story\/","title":"Our Story","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5885,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5885","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/?p=5885","menu_order":18,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5885,"menu_item_parent":"5869","object_id":"19","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/careers\/","title":"Careers","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":7286,"post_author":"6","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-03-25 15:53:53","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"7286","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/7286\/","menu_order":19,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":7286,"menu_item_parent":"5869","object_id":"149","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/news\/","title":"Company News","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5939,"post_author":"2","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 17:42:17","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5939","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5939","menu_order":20,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5939,"menu_item_parent":"5869","object_id":"364","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/contact-us\/","title":"Contact Us","target":"","attr_title":"","description":"","classes":[""],"xfn":""}]},{"ID":5870,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"Resource Library","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"resource-library","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5870","menu_order":21,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5870,"menu_item_parent":"0","object_id":"5870","object":"custom","type":"custom","type_label":"Custom Link","title":"Resource Library","url":"#","target":"","attr_title":"","description":"","classes":[""],"xfn":"","children":[{"ID":5878,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5878","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":141,"guid":"https:\/\/www.certisoncology.com\/?p=5878","menu_order":22,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5878,"menu_item_parent":"5870","object_id":"143","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/resources\/cancer-market-facts\/","title":"Cancer Facts","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5879,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5879","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":141,"guid":"https:\/\/www.certisoncology.com\/?p=5879","menu_order":23,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5879,"menu_item_parent":"5870","object_id":"145","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/resources\/clinical-results\/","title":"Clinical Results","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5880,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5880","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":141,"guid":"https:\/\/www.certisoncology.com\/?p=5880","menu_order":24,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5880,"menu_item_parent":"5870","object_id":"147","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/resources\/supporting-research\/","title":"Supporting Research","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":7243,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-02-29 01:36:09","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"7243","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":141,"guid":"https:\/\/www.certisoncology.com\/?p=7243","menu_order":25,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":7243,"menu_item_parent":"5870","object_id":"7237","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/resources\/media\/","title":"Media","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":7296,"post_author":"6","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-03-25 20:25:22","post_content":"","post_title":"White Papers","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"white-papers","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=7296","menu_order":26,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":7296,"menu_item_parent":"5870","object_id":"7296","object":"custom","type":"custom","type_label":"Custom Link","title":"White Papers","url":"https:\/\/whitepapers.certisoncology.com\/","target":"","attr_title":"","description":"","classes":[""],"xfn":""}]},{"ID":5871,"post_author":"1","post_date":"2024-04-09 20:02:44","post_date_gmt":"2024-01-13 00:10:52","post_content":"","post_title":"Contact","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"contact","to_ping":"","pinged":"","post_modified":"2024-04-09 20:02:44","post_modified_gmt":"2024-04-09 20:02:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5871","menu_order":27,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5871,"menu_item_parent":"0","object_id":"364","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/contact-us\/","title":"Contact","target":"","attr_title":"","description":"","classes":[""],"xfn":""}]}"></navigation> <div class="page archive--news"> <component-5f6e4af53220e :arr="{"default":false,"group":{"image":{"ID":2049,"id":2049,"title":"certis-hero-father-default","filename":"certis-hero-father-default.jpg","filesize":89774,"url":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default.jpg","link":"https:\/\/www.certisoncology.com\/resources\/cancer-market-facts\/certis-hero-father-default\/","alt":"","author":"1","description":"","caption":"","name":"certis-hero-father-default","status":"inherit","uploaded_to":143,"date":"2020-12-01 00:56:04","modified":"2020-12-01 00:56:04","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.certisoncology.com\/wp-includes\/images\/media\/default.png","width":1280,"height":320,"sizes":{"thumbnail":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-720x180.jpg","medium-width":300,"medium-height":75,"medium_large":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-768x192.jpg","medium_large-width":768,"medium_large-height":192,"large":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-960x240.jpg","large-width":960,"large-height":240,"1536x1536":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default.jpg","1536x1536-width":1280,"1536x1536-height":320,"2048x2048":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default.jpg","2048x2048-width":1280,"2048x2048-height":320,"small":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-540x135.jpg","small-width":540,"small-height":135,"square-sm":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-540x320.jpg","square-sm-width":540,"square-sm-height":320,"square-md":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-720x320.jpg","square-md-width":720,"square-md-height":320,"portrait":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-640x320.jpg","portrait-width":640,"portrait-height":320,"landscape":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/certis-hero-father-default-960x320.jpg","landscape-width":960,"landscape-height":320}},"text-overlay":{"ID":1018,"id":1018,"title":"hero-headline_certainty-empowers","filename":"hero-headline_certainty-empowers.svg","filesize":3979,"url":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","link":"https:\/\/www.certisoncology.com\/?attachment_id=1018","alt":"","author":"1","description":"","caption":"","name":"hero-headline_certainty-empowers","status":"inherit","uploaded_to":24,"date":"2020-10-13 20:56:30","modified":"2020-10-13 21:01:16","menu_order":0,"mime_type":"image\/svg+xml","type":"image","subtype":"svg+xml","icon":"https:\/\/www.certisoncology.com\/wp-includes\/images\/media\/default.png","width":0,"height":0,"sizes":{"thumbnail":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","thumbnail-width":1,"thumbnail-height":1,"medium":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","medium-width":1,"medium-height":1,"medium_large":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","medium_large-width":1,"medium_large-height":1,"large":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","large-width":1,"large-height":1,"1536x1536":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","1536x1536-width":1,"1536x1536-height":1,"2048x2048":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","2048x2048-width":1,"2048x2048-height":1,"small":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","small-width":1,"small-height":1,"square-sm":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","square-sm-width":1,"square-sm-height":1,"square-md":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","square-md-width":1,"square-md-height":1,"portrait":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","portrait-width":1,"portrait-height":1,"landscape":"https:\/\/www.certisoncology.com\/wp-content\/uploads\/hero-headline_certainty-empowers.svg","landscape-width":1,"landscape-height":1}}}}"></component-5f6e4af53220e><component-5f7ce5112adb2 :singular="""" :arr="[{"ID":507,"post_author":"1","post_date":"2024-03-25 15:45:56","post_date_gmt":"2020-10-06 22:27:35","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"507","to_ping":"","pinged":"","post_modified":"2024-03-25 15:45:56","post_modified_gmt":"2024-03-25 15:45:56","post_content_filtered":"","post_parent":120,"guid":"http:\/\/certisoncology.com\/?p=507","menu_order":1,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":507,"menu_item_parent":"0","object_id":"124","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/mission-vision-values\/","title":"Mission, Vision & Values","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":508,"post_author":"1","post_date":"2024-03-25 15:45:56","post_date_gmt":"2020-10-06 22:27:35","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"508","to_ping":"","pinged":"","post_modified":"2024-03-25 15:45:56","post_modified_gmt":"2024-03-25 15:45:56","post_content_filtered":"","post_parent":120,"guid":"http:\/\/certisoncology.com\/?p=508","menu_order":2,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":508,"menu_item_parent":"0","object_id":"126","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/our-team\/","title":"Team","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":4577,"post_author":"6","post_date":"2024-03-25 15:45:56","post_date_gmt":"2022-08-01 16:14:13","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"4577","to_ping":"","pinged":"","post_modified":"2024-03-25 15:45:56","post_modified_gmt":"2024-03-25 15:45:56","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/4577\/","menu_order":3,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":4577,"menu_item_parent":"0","object_id":"4361","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/our-story\/","title":"Our Story","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":509,"post_author":"1","post_date":"2024-03-25 15:45:56","post_date_gmt":"2020-10-06 22:27:35","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"509","to_ping":"","pinged":"","post_modified":"2024-03-25 15:45:56","post_modified_gmt":"2024-03-25 15:45:56","post_content_filtered":"","post_parent":120,"guid":"http:\/\/certisoncology.com\/?p=509","menu_order":4,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":509,"menu_item_parent":"0","object_id":"19","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/careers\/","title":"Careers","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":7284,"post_author":"6","post_date":"2024-03-25 15:52:33","post_date_gmt":"2024-03-25 15:52:33","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"7284","to_ping":"","pinged":"","post_modified":"2024-03-25 15:52:33","post_modified_gmt":"2024-03-25 15:52:33","post_content_filtered":"","post_parent":120,"guid":"https:\/\/www.certisoncology.com\/7284\/","menu_order":5,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":7284,"menu_item_parent":"0","object_id":"149","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/about-us\/news\/","title":"Company News","target":"","attr_title":"","description":"","classes":[""],"xfn":""},{"ID":5946,"post_author":"2","post_date":"2024-03-25 15:52:33","post_date_gmt":"2024-01-13 18:01:22","post_content":" ","post_title":"","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"5946","to_ping":"","pinged":"","post_modified":"2024-03-25 15:52:33","post_modified_gmt":"2024-03-25 15:52:33","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?p=5946","menu_order":6,"post_type":"nav_menu_item","post_mime_type":"","comment_count":"0","filter":"raw","db_id":5946,"menu_item_parent":"0","object_id":"364","object":"page","type":"post_type","type_label":"Page","url":"https:\/\/www.certisoncology.com\/contact-us\/","title":"Contact Us","target":"","attr_title":"","description":"","classes":[""],"xfn":""}]"></component-5f7ce5112adb2> <component-5f8f6262a8d2a :arr="{"items":[{"ID":7543,"post_author":"6","post_date":"November 18, 2024","post_date_gmt":"2024-11-18 22:05:38","post_content":"\nZero Deficiencies Noted by HHS Inspectors<\/em><\/p>\n\n\n\nSan Diego, Calif. \u2014 November 18, 2024 \u2013 Certis Oncology Solutions, an AI-enabled precision oncology and translational science company, is pleased to announce that it has received notification from the U.S. Department of Health and Human Services (HHS) confirming the successful completion of its Clinical Laboratory Improvement Amendments (CLIA) inspection. This was the second recertification since the company first secured a CLIA license in 2018 and represents an uninterrupted record of HHS inspections resulting in \u201czero deficiencies\u201d\u2014a notable accomplishment for any regulated laboratory.<\/p>\n\n\n\nCLIA inspections, which are conducted by the Centers for Medicare & Medicaid Services (CMS), are a rigorous process designed to ensure clinical laboratories adhere to strict standards regarding test procedures, equipment, personnel qualifications, and quality control. The flawless inspection result highlights the company\u2019s continuous investment in quality control measures and a dedicated team of scientists who prioritize precision.<\/p>\n\n\n\n\"We are extremely proud of the company\u2019s record for quality and regulatory compliance,\u201d said Peter Ellman, Certis President and CEO. \"This first-pass, zero observations CLIA re-certification is a testament to our team's dedication, expertise, and unwavering commitment to delivering the highest level of science to our clients and the patients we serve.\"<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nAbout Certis Oncology Solutions<\/strong> Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company\u2019s product is Oncology Intelligence\u00ae<\/sup> \u2014 highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials.<\/p>\n\n\n\nSince its founding in 2016, Certis has offered <a href=\"https:\/\/www.certisoncology.com\/for-oncologists\/\">personalized functional testing<\/a> to help inform individual cancer treatment decisions, an approach gaining wide support from cancer researchers and oncology clinicians worldwide. Using our patent-pending <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\">artificial intelligence\/machine learning platform<\/a> and more clinically relevant, <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/custom-model-development\/\">patient-derived tumor models<\/a>, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in Sorrento Valley, the heart of San Diego\u2019s life sciences industry.<\/p>\n\n\n\nFor more information about Certis, visit <a href=\"https:\/\/www.certisoncology.com\/\">www.certisoncology.com<\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Receives CLIA Recertification","post_excerpt":"CLIA inspections, which are conducted by the Centers for Medicare & Medicaid Services (CMS), are a rigorous process designed to ensure clinical laboratories adhere to strict standards regarding test procedures, equipment, personnel qualifications, and quality control.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-receives-clia-recertification","to_ping":"","pinged":"","post_modified":"2024-11-18 22:12:38","post_modified_gmt":"2024-11-18 22:12:38","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7543","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-receives-clia-recertification\/","post_thumbnail":false},{"ID":7489,"post_author":"6","post_date":"April 10, 2024","post_date_gmt":"2024-04-10 04:53:00","post_content":"\nSan Diego, Calif. \u2014 April 10, 2024 \u2013 Certis Oncology presented its latest transformational cancer research at the 2024 Annual Meeting of the American Association for Cancer Research April 7-10 at the San Diego Convention Center.<\/p>\n\n\n\nAt this year\u2019s event, Certis scientists highlighted the applications of the company\u2019s patent-pending, predictive artificial intelligence\/machine learning (AI\/ML) platform, CertisAI\u2122 for precision medicine and early drug development, and illustrated the importance of using clinically relevant preclinical models when testing cell therapies and researching difficult-to-treat brain cancers.<\/p>\n\n\n\nFour Certis scientific posters were presented.<\/strong> \u2022 Assessing Machine Learning Models of Drug Response Predictions Using Orthotopic Patient-Derived Xenografts<\/p>\n\n\n\n\u2022 Integrating Artificial Intelligence and Functional Precision Oncology for Individualized Cancer Therapies<\/p>\n\n\n\n\u2022 Evaluation Of Autologous and Allogeneic T-Cell-Based Therapies in Ex Vivo And In Vivo Xenograft Tumors<\/p>\n\n\n\n\u2022 A Multi-Targeted Approach to Evaluate Therapeutic Selection and Efficacy in Preclinical Glioblastoma (GBM) Models<\/p>\n\n\n\nAbstracts and PDF downloads of all posters are <a href=\"https:\/\/info.certisoncology.com\/aacr-2024\" target=\"_blank\" rel=\"noreferrer noopener\">available here<\/a>. <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Presented Cancer Research at AACR Annual Meeting","post_excerpt":"At this year\u2019s event, Certis scientists highlighted the applications of the company\u2019s patent-pending, predictive artificial intelligence\/machine learning (AI\/ML) platform, CertisAI\u2122 for precision medicine and early drug development, and illustrated the importance of using clinically relevant preclinical models when testing cell therapies and researching difficult-to-treat brain cancers.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-at-aacr-annual-meeting","to_ping":"","pinged":"","post_modified":"2024-09-24 17:07:33","post_modified_gmt":"2024-09-24 17:07:33","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7489","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-at-aacr-annual-meeting\/","post_thumbnail":false},{"ID":7271,"post_author":"6","post_date":"January 17, 2024","post_date_gmt":"2024-01-17 21:58:00","post_content":"\nCOMPANY NAMES JOHN R. TOZZI AS NEW BOARD CHAIRMAN<\/strong><\/p>\n\n\n\nSan Diego, Calif.<\/strong> \u2014 January 17, 2024. \u2014 Certis Oncology Solutions (Certis), a precision oncology and translational science company focused on combining AI-directed drug development with advanced functional testing, today announced that it raised $10 million in a Series C funding round, bringing total raised to $42 million. The company also named John R. Tozzi Chairman of its Board of Directors.<\/p>\n\n\n\n\u201cWe welcome John\u2019s leadership and this additional investment at this critical inflection point for our company,\u201d said Peter Ellman, President and CEO of Certis. \u201cNow serving more than 120 oncology therapeutics companies, we have established the necessary business traction to see a clear path to profitable growth. At the same time, ongoing validation studies give us great confidence that our proprietary CertisAI\u2122 predictive oncology platform soon will be able to deliver truly personalized cancer treatment at scale.\u201d<\/p>\n\n\n\nNew Certis Board of Directors Chairman, John Tozzi, who also serves as the Certis Chairman of the Executive and Finance Committees, led the company\u2019s last two internal funding rounds, as well as this most recent raise in which 94% of the company\u2019s top 50 investors participated.<\/p>\n\n\n\n\u201cOur investors are passionate about the company\u2019s patient-focused mission and 100% behind its three-pronged strategy for creating shareholder value: building a best-in-class bank of advanced tumor models for cancer research, developing disruptive AI-based intellectual property, and generating services revenue from very specialized contract research to help fund R&D,\" John Tozzi said.<\/p>\n\n\n\nIn 1982 Mr. Tozzi founded Cambridge Investments LLC, an investment management firm, and continues to serve as its CEO and CIO.<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. The company\u2019s product is Certis Oncology Intelligence\u00ae \u2014 highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials.<\/p>\n\n\n\nSince its founding in 2016, Certis has offered <a href=\"https:\/\/www.certisoncology.com\/for-oncologists\/\" target=\"_blank\" rel=\"noreferrer noopener\">personalized functional testing<\/a> to help inform individual cancer treatment decisions, an approach gaining wide support from cancer researchers and oncology clinicians worldwide. Using our patent-pending <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\" target=\"_blank\" rel=\"noreferrer noopener\">artificial intelligence\/machine learning platform<\/a>, and more clinically relevant, <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/custom-model-development\/\" target=\"_blank\" rel=\"noreferrer noopener\">patient-derived tumor models<\/a>, we bring certainty to drug development decisions and help secure clear and compelling evidence of drug efficacy. Certis operates a CLIA-certified laboratory in Sorrento Valley, the heart of San Diego\u2019s life sciences industry.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Announces Closing of $10 Million Series C Fundraising Round","post_excerpt":"Certis Oncology Solutions (Certis), a precision oncology and translational science company focused on combining AI-directed drug development with advanced functional testing, today announced that it raised $10 million in a Series C funding round, bringing total raised to $42 million. The company also named John R. Tozzi Chairman of its Board of Directors.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-announces-closing-of-10-million-series-c-fundraising-round","to_ping":"","pinged":"","post_modified":"2024-06-03 16:31:44","post_modified_gmt":"2024-06-03 16:31:44","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7271","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-announces-closing-of-10-million-series-c-fundraising-round\/","post_thumbnail":false},{"ID":7288,"post_author":"6","post_date":"November 15, 2023","post_date_gmt":"2023-11-15 16:55:00","post_content":"\nPresentation to highlight predictive power of CertisAI\u2122\u00a0approach to predict and test combination therapies for Glioblastoma Multiforme<\/em><\/p>\n\n\n\nSan Diego, Calif. \u2014 November 15, 2023 \u2013 Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract discussing a study evaluating AI-directed combination therapies for the treatment of glioblastoma multiforme (GBM), which will be presented at the Society for NeuroOncology (SNO) Annual meeting to be held in Vancouver, Canada November 16-19, 2023.<\/p>\n\n\n\nGlioblastoma multiforme (GBM) is a devastating primary brain cancer with nearly 15,000 new cases annually in the United States. The disease is typically treated with surgery, radiation therapy and temozolomide, but almost always recurs following treatment. This suggests the need for novel treatment approaches.<\/p>\n\n\n\n\u201cCertis Oncology was founded to upend the status quo in cancer treatment, whereby one-size-first all therapeutic approaches continue to be used despite high failure rates in treating complex cancers like GBM,\u201d said Peter Ellman, CEO of Certis Oncology. \u201cThis research aims to nudge the community towards using predictive artificial intelligence and functional testing to accelerate the use of combinatorial strategies and advance personalized cancer care.\u201d<\/p>\n\n\n\nAbstract EXTH-61: A Multi-Targeted Approach to Evaluate Therapeutic Selection and Efficacy in Preclinical GBM Models<\/strong> Poster session:<\/strong> Friday, November 17, 2023, 7:30-9:30 pm PDT Abstract: <\/strong>Recent studies have suggested the utilization of combination therapy approaches for GBM patients to address temozolomide resistance. Certis developed a personalized, AI-based approach to predict and test combination therapies for GBM using tissue samples from an initial GBM incidence and recurrence following treatment. Accuracy of the predicted sensitives to treatment was then evaluated in vivo using both subcutaneously and orthotopically engrafted mouse models. Optical bioluminescence imaging (BLI) and MRI were used to assess therapeutic response of AI-predicted combination therapies and standard or care. Analysis confirmed a high degree of fidelity between the AI predictions and the observed analysis of the models thereby demonstrating the value of a novel, combinatorial platform for the assessment of therapeutic efficacy in GBM.<\/p>\n\n\n\n<a href=\"https:\/\/www.certisoncology.com\/wp-content\/uploads\/2023_Certis-SNO-Poster_-EXTH-61-1.pdf?hsCtaTracking=dc3a19a7-63e3-4349-a6b0-c0c201152289%7C67c90722-0a7a-4ad4-b656-f7176a967f3a\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to download the poster.<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/about-us\/who-we-are\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from AI-enabled insights and validated in advanced biological models of cancer. Our proprietary platform can help inform individual treatment decisions and accelerate the development of new cancer therapies. <a href=\"https:\/\/www.certisoncology.com\/innovations-in-gbm-model-development\/\" target=\"_blank\" rel=\"noreferrer noopener\">Learn more<\/a> about clinically relevant orthotopic PDX models, focal radiation and more for your preclinical GBM studies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Announces Presentation Of Abstract at SNO Annual Meeting","post_excerpt":"Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract discussing a study evaluating AI-directed combination therapies for the treatment of glioblastoma multiforme (GBM).<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-announces-presentation-of-abstract-at-sno-annual-meeting","to_ping":"","pinged":"","post_modified":"2024-06-03 16:30:14","post_modified_gmt":"2024-06-03 16:30:14","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7288","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-announces-presentation-of-abstract-at-sno-annual-meeting\/","post_thumbnail":false},{"ID":7269,"post_author":"6","post_date":"November 9, 2023","post_date_gmt":"2023-11-09 21:50:00","post_content":"\nSan Diego, Calif. \u2014 November 9, 2023 \u2013 Certis Oncology Solutions (Certis), a translational science and precision oncology company, today announced it has been selected as \"Overall Immunology Company of the Year\" in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services.<\/p>\n\n\n\n\u201cWe are honored to have received this recognition,\u201d said Peter Ellman, President and Chief Executive Officer at Certis Oncology Solutions. \u201cOur company was founded in 2016 to serve patients who were out of standard-of-care options, providing functional evaluations of drug response in personalized mouse avatars to help guide late-stage treatment. Today, we are pairing deep expertise in patient-derived model development with AI-enabled predictions of drug response to accelerate the journey to truly personalized medicine. In addition to the obvious future clinical applications of this platform, there are immediate benefits for those who leverage it to accelerate drug discovery and improve preclinical decision-making.\u201d<\/p>\n\n\n\nCertis began offering preclinical and translational research services to the pharmaceutical industry in 2021, and has since built a rapidly growing library of over 450 highly characterized tumor models for pharmaceutical research. The company has pioneered work on humanized orthotopic patient-derived xenograft (huO-PDX) models, which are especially relevant to studying immunotherapies for solid tumor types and mechanisms that target the tumor microenvironment (TME). Certis performs a variety of live cell and other assays to support the industry\u2019s need for the preclinical development of immunotherapies, with an emphasis on evaluating CAR-T therapies.<\/p>\n\n\n\nEarlier this year, the company launched CertisAI\u2122, a new predictive artificial intelligence platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers. CertisAI\u2122 is a pan-cancer solution that enables researchers to effectively replace many discovery screening studies with in silico predictions, and save time and money by bringing computer-aided insight to inform critical development decisions. The CertisAI\u2122 platform also holds great promise in clinical settings, using an individual\u2019s genetic profile to predict drug response to a variety of drugs and combination therapies. Certis is presently engaged in an observational research study aimed at validating predictions and repurposing existing drugs for difficult-to-treat colorectal cancers.<\/p>\n\n\n\n<a href=\"https:\/\/news.certisoncology.com\/cs\/c\/?cta_guid=e88b5a8d-f7ec-4899-94cf-04845f5cd60f&signature=AAH58kEqyfDwAxZ6NIJlju9ngnJr0UeeBQ&pageId=144622388605&placement_guid=93edb6da-de00-42a8-b407-be6c264a3929&click=375c854d-3244-49b9-bcd3-55a0940f877a&hsutk=2b71acbac55f466d5d63fc5db3d720e7&canon=https%3A%2F%2Fnews.certisoncology.com%2Fcertis-oncology-named-overall-immunology-company-of-the-year-in-2023-biotech-breakthrough-awards&utm_referrer=https%3A%2F%2Fnews.certisoncology.com%2Fpage%2F1&portal_id=7965310&redirect_url=APefjpFdZQPkSf03vTjrf_gD-N_BRHn2sHlEu6lQnNCS4WcRcKbb8dKdabKpZT4DAiSB2PJFcjIZrYmHZJsf5_I2HS-x75XMOJBBjgt37fe6UmFmAN6Ivf8RtZwyEUKDJ5DJb5_ybo85Y3RipTUmxXNgWHdQJr0t8DHk0eAyOvxNfN3K0d-SfWzaw91A19XFasESpV1kTJhSN0oHhHpIL5l5eM_GXEG_Gz2y6-SFQQPQCjc-Klhls602-iz9ryrJ3l2lrPa4516Ns7GFw2QJaMSOjub4XSIItpUk2weznkIzOx4Qgk96XUo&__hstc=234873281.2b71acbac55f466d5d63fc5db3d720e7.1686332604548.1710867960268.1710877292300.428&__hssc=234873281.48.1710877292300&__hsfp=3619869213&contentType=blog-post\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to learn more.<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from AI-enabled insights and validated in advanced biological models of cancer. We partner with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Using our proprietary artificial intelligence\/machine learning platform and more clinically relevant, patient-derived tumor models, we bring certainty to lead candidate selection and help secure clear and compelling evidence of drug efficacy. Established in 2016, Certis operates a CLIA-certified laboratory in Sorrento Valley, the heart of San Diego\u2019s life sciences industry.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Named 'Overall Immunology Company of the Year' In 2023 Biotech Breakthrough Awards","post_excerpt":"Certis Oncology Solutions (Certis), a translational science and precision oncology company, today announced it has been selected as “Overall Immunology Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-named-overall-immunology-company-of-the-year-in-2023-biotech-breakthrough-awards","to_ping":"","pinged":"","post_modified":"2024-03-27 17:17:04","post_modified_gmt":"2024-03-27 17:17:04","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7269","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-named-overall-immunology-company-of-the-year-in-2023-biotech-breakthrough-awards\/","post_thumbnail":false},{"ID":7268,"post_author":"6","post_date":"November 1, 2023","post_date_gmt":"2023-11-01 09:42:00","post_content":"\nPRESENTATION TO HIGHLIGHT IMPORTANCE OF STUDY DESIGN IN EVALUATING ANTI-TUMOR EFFECTS OF IMMUNOTHERAPIES IN PRECLINICAL MODELS<\/strong><\/p>\n\n\n\nSan Diego, Calif. \u2014 November 1, 2023 \u2013 Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, Calif. November 1-5, 2023.<\/p>\n\n\n\n\u201cThe growing use of immunotherapies to treat cancers must be met with a re-examination of the preclinical research methods used to study new therapeutics in development,\u201d said Peter Ellman, CEO of Certis Oncology Solutions. \u201cOur research illustrates the variation of results that can be achieved using different types of preclinical mouse models to study immunotherapy compounds and shows the importance of selecting models that are best capable of recapitulating the complexities of the human immune system and tumor microenvironment.\u201d<\/p>\n\n\n\nCertis scientists will discuss results from a study which compared differences in gene expression influenced by the tumor microenvironment in humanized patient-derived xenograft models of cancers. The study sought to demonstrate differences in overall immune response and pharmacological outcome when comparing results from PDX models with subcutaneous and orthotopic implantation sites. <\/p>\n\n\n\nAbstract Number 1453: \"In Vivo Tumor Implantation Site Exhibits Differential Immune Response in Solid Tumors\"<\/strong> Poster Session:<\/strong> Friday, Nov. 3, 2023, 9 am\u20137pm Abstract:<\/strong> Historically, patient-derived xenograft (PDX) modeling involves subcutaneous implantation which minimally represents the actual human tumor site, as opposed to orthotopic implantation (O-PDX) which more accurately reflects the local tumor microenvironment. This study compared both types of PDX models as well as humanized PDX models developed using peripheral blood mononuclear cells (PBMC), to demonstrate the differences in the effectiveness of each model. The research showed significant pathways altered between the models, including immunoregulatory interactions between the PDX and O-PDX models, and showed differences in presence of tumor infiltrating lymphocytes as well as differential in vivo<\/em> efficacy and immunophenotypes in the PBMC humanized mice treated with checkpoint inhibiting compounds.<\/p>\n\n\n\n<a href=\"https:\/\/news.certisoncology.com\/cs\/c\/?cta_guid=c504356b-200b-4489-9d80-e0bb5f09b25c&signature=AAH58kHiE8Y56BMHuy7cNosm6sjwDL8YXQ&pageId=144457008210&placement_guid=f5e48d8c-a02c-4d58-ae22-725e576d6bd0&click=ab290179-b223-424a-a353-a0a7afd7dfc3&hsutk=2b71acbac55f466d5d63fc5db3d720e7&canon=https%3A%2F%2Fnews.certisoncology.com%2Fcertis-oncology-solutions-announces-presentation-of-abstract-at-society-for-immunotherapy-of-cancer-annual-meeting&utm_referrer=https%3A%2F%2Fnews.certisoncology.com%2Fpage%2F1&portal_id=7965310&redirect_url=APefjpEkBalrcnDBNbIaRuKJiZtOm9Gaf9Q9Pt0DN_A6FNEPzsvOVhajfbXYCHrCmqvrXuLuiz1d935vckC_7KWBK9s-vfbao9Xcl2-Xbvakvdo1syywNn0djOZ_zf9ai5exQEV7GLRmTeGNbTsDioZ2V_TrZO1U1XXOTKD46B87U8AfYWXXw-38DWZdSizbSBShBJRDKTp0Hht9ivtxiX9wpd0EPGKspU85MR-4fri-Maur-4i7HmLaUEONnN7I20S1JaBiVz8hCAZMLlQMrmozeDGXQqE4PXBOOfuh35lq3REsfnFsXz6B1Hq7a-96_tgb5ghGnf_6C1CeqV8ReACmKV31KqQViw&__hstc=234873281.2b71acbac55f466d5d63fc5db3d720e7.1686332604548.1710867960268.1710877292300.428&__hssc=234873281.45.1710877292300&__hsfp=3619869213&contentType=blog-post\" target=\"_blank\" rel=\"noreferrer noopener\">Click here<\/a> to download the poster.<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Solutions Announces Presentation of Abstract at Society For Immunotherapy of Cancer Annual Meeting","post_excerpt":"Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-solutions-announces-presentation-of-abstract-at-society-for-immunotherapy-of-cancer-annual-meeting","to_ping":"","pinged":"","post_modified":"2024-03-27 17:17:27","post_modified_gmt":"2024-03-27 17:17:27","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7268","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-solutions-announces-presentation-of-abstract-at-society-for-immunotherapy-of-cancer-annual-meeting\/","post_thumbnail":false},{"ID":7267,"post_author":"6","post_date":"August 3, 2023","post_date_gmt":"2023-08-03 09:10:00","post_content":"\nACCELERATING THE DEVELOPMENT OF NOVEL LINEBACKER COMPOUND<\/strong><\/p>\n\n\n\nGarden City, NY \u2013 August 3, 2023 \u2013 ProPhase Labs, Inc. (NASDAQ: PRPH) (\u201cProPhase\u201d), a next generation biotech, genomics, therapeutics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor that is being developed by the Company\u2019s wholly owned subsidiary, ProPhase BioPharma, Inc. (\u201cPBIO\u201d), as a potential safer, more efficacious oncology therapy wholly unlike standard chemotherapeutic agents.<\/p>\n\n\n\n\u201cProPhase Labs continues to act as a disruptor in the therapeutic development space by employing only the most advanced, cutting-edge technology in the pursuit of clinical benefit and program success,\u201d commented developmental lead Dr. Matt Halpert Ph.D. \u201cLong gone are the days of blind experimentation with the hopes of achieving promising results. We have entered an era in which if you are not at the forefront of high throughput analysis and technology for therapeutical development, you are not in therapeutical development.\u201d<\/p>\n\n\n\nWith that mindset, ProPhase Labs has joined forces with Certis Oncology to use one-of-a-kind, robust, machine learning technology to exponentially improve the chances of successful development in the oncological therapeutic space.<\/p>\n\n\n\n\u201cWe have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,\u201d says Ted Karkus, CEO of ProPhase Labs. \u201cBy further mining all existing data sets, we are able to cross-reference genetic signatures, signaling pathways, and Linebacker responsiveness with Artificial Intelligence (AI), which we believe will greatly assist us in honing in on the most likely cancers and pathways that may be inhibited by Linebacker in the big picture.\u201d<\/p>\n\n\n\n\u201cUsing Certis\u2019 proprietary technology, <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\" target=\"_blank\" rel=\"noreferrer noopener\">CertisAI\u2122 Predictive Oncology Intelligence<\/a>, we determined that Linebacker may be effective against several types of cancer, but importantly not all cancers,\u201d Dr. Halpert continued. \u201cSelectivity is good, and being able to determine now what is most likely to be clinically relevant only improves the overall odds of success.\u201d<\/p>\n\n\n\nProPhase intends to continue to line up AI-generated information with sound medical and scientific insights from experienced players to further guide development towards a regulatory pathway with lower barriers to entry and severe need in the clinic.<\/p>\n\n\n\n\u201cOur team is very pleased to be working with ProPhase on the Linebacker initiative. By leveraging the predictive power of artificial intelligence and machine learning, then validating in silico predictions using advanced, more clinically relevant biological models of cancer, the scientific community will answer complex questions about how to treat each unique cancer\u2014faster,\u201d said Peter Ellman, President and CEO of Certis.<\/p>\n\n\n\n\u201cOf course, this is more work on the front end, but it would be short-sighted and disingenuous to forego these opportunities to protect against a future, exponentially larger, burn,\u201d added Karkus. \u201cSavvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward. We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies. This is a nominal amount given our greater than $40 million in net working capital. With positive results and subject to the necessary regulatory approvals, we believe we will be well situated to explore significant licensing opportunities with major pharma.\u201d<\/p>\n\n\n\nWith this extensive data set now in hand, ProPhase will proceed to the next level of IND-enabling development for the potentially revolutionary Linebacker drug. Focused and detailed studies are already underway.<\/p>\n\n\n\nABOUT LINEBACKER<\/strong> Linebacker is a modified polyphenol. Polyphenols are substances found in many nuts, vegetables and berries. Linebacker compounds are modified Myricetin, which is a common plant-derived flavonoid. Myricetin exhibits a wide range of activities that include strong antioxidant, anti-cancer, anti-diabetic and anti-inflammatory activities. It displays activities that are related to the central nervous system.<\/p>\n\n\n\nLB-1 is Mono-chlorinated Myricetin with a Chlorine atom substituted for the Hydroxy group at 5\u2019 (position 5 on the B-ring). LB-2 is Di-chlorinated Myricetin with Chlorine atoms substituted for the Hydroxy groups at 5\u2019 and 7 (position 5 on the B-ring and position 7 on the A-ring).<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform can help inform personalized cancer care and accelerates the development of new cancer therapies. <\/p>\n\n\n\nABOUT PROPHASE LABS<\/strong> <a href=\"https:\/\/news.certisoncology.com\/prophase-labs-teams-up-with-certis-oncology#:~:text=ABOUT%20PROPHASE%20LABS-,ProPhase%20Labs%2C%20Inc.,-(Nasdaq%3A%20PRPH)%20(%E2%80%9CProPhase\" target=\"_blank\" rel=\"noreferrer noopener\">ProPhase Labs, Inc.<\/a> (Nasdaq: PRPH) (\u201cProPhase\u201d) is a next-generation biotech, genomics, therapeutics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. They are revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Their world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. ProPhase develops, manufactures and commercializes health and wellness solutions to enable people to live their best lives. They are are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs\u2019 valuable subsidiaries, their synergies, and significant growth underscore their multi-billion-dollar potential.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACTS Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n\n\n\nProPhase Labs, Inc. 267-880-1111 investorrelations@prophaselabs.com<\/p>\n","post_title":"Prophase Labs Teams Up With Certis Oncology","post_excerpt":"ProPhase Labs, Inc. (NASDAQ: PRPH) (\u201cProPhase\u201d), a next generation biotech, genomics, therapeutics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"prophase-labs-teams-up-with-certis-oncology","to_ping":"","pinged":"","post_modified":"2024-03-27 17:19:00","post_modified_gmt":"2024-03-27 17:19:00","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7267","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/prophase-labs-teams-up-with-certis-oncology\/","post_thumbnail":false},{"ID":7265,"post_author":"6","post_date":"June 8, 2023","post_date_gmt":"2023-06-08 08:42:00","post_content":"\nOPTIMIZING BIOMARKER DISCOVERY, MODEL SELECTION AND PRECLINICAL DECISION-MAKING<\/strong><\/p>\n\n\n\nSan Diego, CA \u2013 June 8, 2023 \u2013 SOTERIA Precision Medicine Foundation (\"SOTERIA\"), an organization dedicated to empowering patients, caregivers, and clinicians with the power of precision medicine, today announced a fiscal sponsorship agreement with Certis Oncology Solutions (\"Certis\"), a San Diego-based precision oncology and translational science company. The agreement will support an observational clinical research study aimed at validating the application of <a href=\"https:\/\/en.wikipedia.org\/wiki\/Mouse_avatars\" target=\"_blank\" rel=\"noreferrer noopener\">mouse avatars<\/a> as a clinically relevant platform for precision oncology and evaluating the clinical utility of the patent-pending CertisAI\u2122 platform, which uses multivariate analyses and gene expression biomarkers to predict drug response. The Project, to be funded through charitable donations, will focus initially on colorectal and other cancers that commonly carry KRAS mutations. All testing will be performed in Certis\u2019 CLIA-certified laboratory.<\/p>\n\n\n\n\u201cSOTERIA was founded to help individuals access the most relevant advanced technology and treatment options, regardless of their treating medical institution, geographic location, or socioeconomic status. By sponsoring this Project for Certis, we not only advocate for what is possible now, we help create what will be possible in the future,\u201d said Julia Civardi, SOTERIA Chief Executive Officer. \u201cToo many people endure a one-size-fits-all, trial-and-error approach to cancer treatment. This project underscores the power of an individual\u2019s unique form of cancer and health data to identify personalized, targeted treatment plans and employs emerging technologies that we hope will one day become mainstream medicine.\u201d<\/p>\n\n\n\nThe genesis of this Project began last year, when the CertisAI platform identified biomarker patterns predictive of positive response to therapies not currently indicated for certain untreatable types of cancer. Certis scientists subsequently performed experiments using mouse models, which validated AI-generated predictions and compelled a deeper interrogation of public in vitro<\/em> and clinical outcomes datasets. All findings point to an opportunity to repurpose existing, FDA-approved drugs to improve clinical outcomes for individuals diagnosed with certain difficult-to-treat cancers.<\/p>\n\n\n\nSOTERIA will provide not-for-profit oversight of the Project, and work alongside Certis to secure private donations earmarked for this study. The first invite-only fundraiser is planned for August 26, 2023, 4-7pm, at The Marine Room in La Jolla, California. To make a donation, <a href=\"https:\/\/www.soteriaprecisionmedicine.org\/donate\" target=\"_blank\" rel=\"noreferrer noopener\">click here<\/a>.<\/p>\n\n\n\nThe study will leverage genomics to identify and understand protein expression signatures unique to each individual\u2019s cancer, use artificial intelligence and machine learning to predict and rank efficacious therapeutic options based upon tumor genomics, and deploy specialized imaging equipment to validate those predictions with murine-scale MRI (Magnetic Resonance Imaging) equipment to monitor disease progression and accurately predict therapeutic response occurring in personalized orthotopic patient-derived xenograft (O-PDX) mouse models of each individual\u2019s cancer. <\/p>\n\n\n\n\u201cThere are many FDA-approved cancer therapies that can be effective in treating a range of cancers, but they have only been studied in limited applications and guidelines are based on historical testing done on inert samples,\u201d said Dr. Sandip Patel, MD, Professor of Medical Oncology at University of California San Diego. \u201cThe technologies at Certis and SOTERIA could help to identify which of those therapies might be most effective in treating patients with otherwise difficult-to-treat cancers with KRAS and other mutations with few FDA-approved therapies, using a living system modeled after the patient\u2019s tumor as the test bed for new therapies.\u201d<\/p>\n\n\n\nSTUDY PROTOCOL COMBINES AI WITH FUNCTIONAL IN VIVO ASSAY<\/strong> Patients with KRAS-mutated cancers selected for participation in the study will undergo a tumor tissue biopsy, which will undergo Whole Exome and RNA sequencing. The tumor\u2019s protein expression signatures will be input into the CertisAI\u2122 platform, which will return potential efficacious therapies, rank-ordered in terms of efficacy. Several AI-predicted therapies will then be tested in parallel, employing very specialized mouse avatars of the patient\u2019s cancer known as <a href=\"https:\/\/aacrjournals.org\/cancerres\/article\/81\/13_Supplement\/3013\/668929\/Abstract-3013-Orthotopic-patient-derived\" target=\"_blank\" rel=\"noreferrer noopener\">orthotopic patient-derived xenograft (O-PDX) models<\/a>. Tumor response to treatment will be monitored using specialized murine-scale MRI equipment to assess the efficacy of each treatment option relative to CertisAI predictions. Study results will provide hypothesis-generating data treating oncologists may use to guide next-line therapy for individuals who have exhausted standard-of-care options \u2014 and feed the CertisAI machine learning algorithms to make the platform smarter. Each personalized study will take approximately six months to complete.<\/p>\n\n\n\nABOUT SOTERIA PRECISION MEDICINE FOUNDATION<\/strong> <a href=\"https:\/\/www.soteriaprecisionmedicine.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">SOTERIA Precision Medicine Foundation<\/a>, a non-profit 501c3 organization, offers direct-to-patient, precision medicine navigation to support patients with cancer and clinicians. Founded by a cancer survivor and a cancer caregiver, both genomics professionals, Julia Civardi and Amanda Skeen have led the organization to support hundreds of cancer patients globally across varying types and stages of cancer. The SOTERIA Precision Cancer Program transcends brick-and-mortar institutions and bridges the gap between rapid scientific advancements and the clinic to address health inequities and inform leading-edge care. SOTERIA\u2019s high-tech, high-touch approach combines traditional clinical data with a patient\u2019s genomic profile to generate a data-based approach to care navigation, deviating from the antiquated one-drug-fits-all approach.<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/for-oncologists\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform can help inform personalized cancer care and accelerate the development of new cancer therapies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACTS SOTERIA Precision Medicine Foundation Amanda Skeen Amanda@soteriaone.com Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"SOTERIA Opens Cancer Research Study Leveraging Certis AI and Functional Assays","post_excerpt":"SOTERIA Precision Medicine Foundation (“SOTERIA”), an organization dedicated to empowering patients, caregivers, and clinicians with the power of precision medicine, today announced a fiscal sponsorship agreement with Certis Oncology Solutions (“Certis”), a San Diego-based precision oncology and translational science company.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"soteria-opens-cancer-research-study-leveraging-certis-ai-and-functional-assays","to_ping":"","pinged":"","post_modified":"2024-03-27 17:19:42","post_modified_gmt":"2024-03-27 17:19:42","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7265","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/soteria-opens-cancer-research-study-leveraging-certis-ai-and-functional-assays\/","post_thumbnail":false},{"ID":7263,"post_author":"6","post_date":"April 25, 2023","post_date_gmt":"2023-04-25 20:31:00","post_content":"\nOPTIMIZING BIOMARKER DISCOVERY, MODEL SELECTION AND PRECLINICAL DECISION-MAKING<\/strong><\/p>\n\n\n\nToronto, ON \u2014 April 25, 2023 \u2014 In this <a href=\"https:\/\/xtalks.com\/webinars\/ai-in-cancer-research-optimizing-biomarker-discovery-model-selection-and-preclinical-decision-making\/?webinar=upcoming#webinar-form-outer\" target=\"_blank\" rel=\"noreferrer noopener\">upcoming live webinar<\/a> hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to preclinical decision-making. Certis Oncology Solutions Director of Bioinformatics and Data Science Long H. Do, PhD, will discuss the application of multivariate, in silico<\/em> analyses of protein expression biomarkers and machine learning (ML) algorithms in drug discovery and companion diagnostics (CDx) development. Attendees will gain insights about using AI to identify biomarkers, prioritize the most promising compounds, rank cancer types most likely to respond to a lead candidate and elucidate potential synergies of combinatorial therapies.<\/p>\n\n\n\nAI-enabled technologies are revolutionizing the drug development process, from target identification and lead optimization to early biomarker validation. By leveraging big data, bioinformatics and ML, cancer drug development and translational research teams can identify novel biomarkers, prioritize leads and make better-informed preclinical decisions. Whether a strategy involves bringing novel cancer therapies to market or repurposing existing drugs, applying AI in cancer research can help unlock the full potential of candidate drugs and expedite the path to approval.<\/p>\n\n\n\nIn this upcoming live webinar, Certis Oncology Solutions Director of Bioinformatics and Data Science Long H. Do, PhD, will explore how in silico<\/em> innovations can bring new insights to oncology translational research and the drug development process.<\/p>\n\n\n\n<a href=\"https:\/\/xtalks.com\/webinars\/ai-in-cancer-research-optimizing-biomarker-discovery-model-selection-and-preclinical-decision-making\/?webinar=upcoming#webinar-form-outer\" target=\"_blank\" rel=\"noreferrer noopener\">AI in Cancer Research: Optimizing Biomarker Discovery, Model Selection and Preclinical Decision-Making<\/a> Tuesday, May 9, 2023, 2pm EDT (11am PDT)<\/p>\n\n\n\nABOUT XTALKS<\/strong> Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps life science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.<\/p>\n\n\n\nXtalks Media Contact: Vera Kovacevic Tel:(416) 977-6555 x371 Email: vkovacevic@xtalks.com<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/predictive-oncology-intelligence\/\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform can help inform personalized cancer care and accelerates the development of new cancer therapies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Upcoming Webinar On AI In Cancer Research","post_excerpt":" In this upcoming live webinar hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to preclinical decision-making. Certis Oncology Solutions Director of Bioinformatics and Data Science Long H. Do, PhD, will discuss the application of multivariate, in silico analyses of protein expression biomarkers and machine learning (ML) algorithms in drug discovery and companion diagnostics (CDx) development.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"upcoming-webinar-on-ai-in-cancer-research","to_ping":"","pinged":"","post_modified":"2024-03-27 17:19:59","post_modified_gmt":"2024-03-27 17:19:59","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7263","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/upcoming-webinar-on-ai-in-cancer-research\/","post_thumbnail":false},{"ID":7261,"post_author":"6","post_date":"April 13, 2023","post_date_gmt":"2023-04-13 08:24:00","post_content":"\nBIOINFORMATICS SOLUTION COMBINES ARTIFICIAL INTELLIGENCE, MACHINE LEARNING AND FUNCTIONAL TESTING TO ELEVATE PRECISION CANCER TREATMENT<\/strong><\/p>\n\n\n\nSan Diego, CA \u2014 April 13, 2023 \u2014 Certis Oncology Solutions (\"Certis\"), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine, today announced the launch of CertisAI\u2122, a new predictive medicine platform that utilizes big data, statistical algorithms,and machine learning (ML) to predict drug efficacy based on gene expression biomarkers. This pan-cancer solution can accelerate drug discovery and companion diagnostics development.<\/p>\n\n\n\nUnlike common single-biomarker strategies often employed in precision medicine, CertisAI uses multivariate ML algorithms to capture the nuance of biomarker interactions and bring greater accuracy to predictions of drug efficacy.<\/p>\n\n\n\n\"When it comes to understanding how to treat a person's cancer, identifying oncogenic DNA mutations is just scratching the surface,\" said Peter Ellman, Certis President and CEO. \"This common approach to precision medicine isn't capturing the nuance of gene expression levels or the complex interrelationships between multiple genetic features. These dynamics are what govern tumor response to any given therapy, but the complexity involved is too great for any human to grapple with. Computer models can,\" he said.<\/p>\n\n\n\nBRINGING AI SUPPORT TO CANCER THERAPEUTIC DEVELOPMENT<\/strong> Despite great progress in cancer research, fewer than 4% of oncology drugs that enter clinical trials are ultimately approved for use.1<\/sup> Many factors contributing to this translation gap in cancer therapeutics could be mitigated by better-informed decision-making early in the development process. With CertisAI, researchers can effectively replace many discovery screening studies with in silico predictions, and save time and money by bringing computer-aided insight to a variety of drug development challenges, such as:<\/p>\n\n\n\n<ul>\n<li>Identifying biomarkers that are predictive of therapeutic response<\/li>\n\n\n\n<li>Uncovering biological pathway mechanisms of action (MOAs)<\/li>\n\n\n\n<li>Ranking cancer types most likely to respond to a lead candidate<\/li>\n\n\n\n<li>Elucidating synergistic potential of combinatory therapies<\/li>\n\n\n\n<li>Selecting optimal cancer models for in vitro<\/em> and in vivo<\/em> validation studies<\/li>\n\n\n\n<li>Developing stratification strategies for clinical trial patient selection<\/li>\n\n\n\n<li>Prioritizing candidates in compound libraries and\/or assessing the value of intellectual property<\/li>\n<\/ul>\n\n\n\nThe origins of CertisAI are rooted in the company's mission: finding the optimal therapy for every cancer patient, the first time, every time. Since its founding in 2016, Certis has been validating a functional approach to personalized medicine using orthotopic patient-derived xenograft (O-PDX) models \u2014 sophisticated mouse models of individual cancers that enable the simultaneous testing of multiple therapeutic options. Data from these studies may be used to help inform oncologists' treatment strategies.<\/p>\n\n\n\nRELIEVING THE VALIDATION BOTTLENECK<\/strong> In addition to developing the predictive platform, Certis is tackling a persistent problem in the AI-driven healthcare landscape \u2014 how to efficiently validate in silico<\/em> predictions. Conducting clinical trials and waiting for long-term outcomes is inherently slow, making validation a bottleneck to progress.<\/p>\n\n\n\nCertis draws on deep experience developing O-PDX models, performing mouse clinical trials to validate CertisAI predictions. Results from these studies generate training data to inform the platform's ML algorithms, improving predictive accuracy.<\/p>\n\n\n\nMost genomic testing companies that include possible matched treatments in their reports consider only drugs already approved for companion biomarkers. The Certis predictive algorithms look outside standard-of-care, including off-label uses of approved drugs as well as investigational drugs in clinically accurate mono and combination therapies (>90% and 83% combined, respectively), and external validation on O-PDX models has shown promising results. <\/p>\n\n\n\nFor more information, register now for our upcoming live webinar on <a href=\"https:\/\/xtalks.com\/webinars\/ai-in-cancer-research-optimizing-biomarker-discovery-model-selection-and-preclinical-decision-making\/\" target=\"_blank\" rel=\"noreferrer noopener\">AI in Cancer Research: Optimizing Biomarker Discovery, Model Selection and Preclinical Decision-Making<\/a>.<\/p>\n\n\n\n<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform can help inform personalized cancer care and accelerates the development of new cancer therapies.<\/p>\n\n\n\nReference:<\/strong> 1 Wong CH, Siah KW, Lo AW. <a href=\"https:\/\/news.certisoncology.com\/for-immediate-release-certis-oncology-solutions-launches-predictive-analytics-platform#:~:text=Estimation%20of%20Clinical%20Trial%20Success%20Rates%20and%20Related%20Parameters\" target=\"_blank\" rel=\"noreferrer noopener\">Estimation of Clinical Trial Success Rates and Related Parameters<\/a>. Biostatistics<\/em>. Apr 1, 2019. 20(2):273-286.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Solutions Launches Predictive Analytics Platform","post_excerpt":"Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine, today announced the launch of CertisAI\u2122, a new predictive medicine platform that utilizes big data, statistical algorithms,and machine learning (ML) to predict drug efficacy based on gene expression biomarkers.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-solutions-launches-predictive-analytics-platform","to_ping":"","pinged":"","post_modified":"2024-03-27 17:20:10","post_modified_gmt":"2024-03-27 17:20:10","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7261","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-solutions-launches-predictive-analytics-platform\/","post_thumbnail":false},{"ID":7260,"post_author":"6","post_date":"April 5, 2023","post_date_gmt":"2023-04-05 08:14:00","post_content":"\nPRESENTATIONS TO HIGHLIGHT THE VALUE OF CLINICALLY RELEVANT PATIENT-DERIVED XENOGRAFT (PDX) MODELS FOR TRANSLATIONAL RESEARCH AND DRUG DEVELOPMENT<\/strong><\/p>\n\n\n\nSan Diego, CA \u2014 April 5, 2023 \u2013 Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine, today announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, FL. from April 14-19, 2023.<\/p>\n\n\n\n\u201cImmunotherapy development to date has largely focused on hematological cancers. As cancer researchers turn their attention to applying immuno-oncology to solid tumors, the need for preclinical models that recapitulate tumor microenvironment is becoming critical,\u201d said Peter Ellman, Certis President and Chief Executive Officer. \u201cOur science shows that immune response to cancer therapies is dramatically different in humanized subcutaneous and orthotopic PDX models\u2014a likely cause of false positives in preclinical immuno-oncology studies. We\u2019re excited to showcase this and other important areas of cancer research at Certis.\u201d<\/p>\n\n\n\nCertis scientists will highlight research in humanized cancer models for immunotherapy, AI and circulating DNA as a clinically relevant biomarker. Session titles and information for the three abstracts are listed below and are now available on the AACR online itinerary planner.<\/p>\n\n\n\nABSTRACT 4299\/30-SECTION 32: GENE EXPRESSION-BASED MACHINE LEARNING CLASSIFIER TO PREDICT AND VALIDATE CANCER TYPE IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS<\/strong> Poster session:<\/strong> April 18, 2023, 9am -12:30pm (EST) Abstract: <\/strong>Patient-derived xenograft (PDX) models are increasingly utilized in translational research and drug development. Characterizing the genomic features of PDX is essential to establishing reliable models for cancer research. Despite great interest, problems remain in PDX tumor data banks, including improper cancer type diagnosis and sample mix-ups. To improve annotation and quality of PDX models, Certis developed a machine learning model trained on gene expression data from the Cancer Genome Atlas (TCGA). Certis then applied the model to corresponding data collected from nearly 300 Certis PDX models as well as the National Cancer Institute\u2019s (NCI) Patient-Derived Models Repository (PDMR). The model shows high precision and variable recall and provides a fast and accurate method for cancer type diagnosis.<\/p>\n\n\n\nABSTRACT 4762\/10-SECTION 6: IN VIVO TUMOR IMPLANTATION SITE EXHIBITS DIFFERENTIAL IMMUNE RESPONSE IN SOLID TUMORS<\/strong> Poster session: <\/strong>April 18, 2023, 1:30 \u2013 5:00pm (EST) Summary:<\/strong> Successful discovery and development of cancer therapeutics depend on testing agents in the most clinically relevant translational models. Emerging evidence highlights the importance of the local tumor microenvironment in evaluating the efficacy of new therapeutics, especially for immunotherapies. Historically, PDX modeling involves subcutaneous implantation which minimally represents the actual human tumor site. Here, Certis uses peripheral blood mononuclear cell (PBMC) humanized PDX models to demonstrate differences in the tumor microenvironment, overall immune response, and the pharmacological outcome, between subcutaneous and orthotopic PDX models. These findings highlight the importance of testing new therapies in the most clinically relevant setting for greater translation into clinical success.<\/p>\n\n\n\nABSTRACT 6690\/10 \u2013 SECTION 40:<\/strong> MONITORING DRUG RESPONSE WITH CIRCULATING TUMOR DNA IN A NON-SMALL CELL LUNG CANCER (NSCLC) PATIENT-DERIVED XENOGRAFT MODEL<\/strong> Poster session:<\/strong> April 19, 2023, 9:00am.-12:30 pm (EST) Abstract:<\/strong> \u202fCirculating tumor DNA (ctDNA) has been shown as a clinically relevant biomarker for non-invasive monitoring of therapy response, disease burden and disease progression in cancer patients.\u202f Patient-derived xenograft (PDX) mice are essential preclinical models to evaluate therapeutic response.\u202fPatients with a KRAS G12 mutation in Non-Small Cell Lung Cancer (NSCLC) have been shown to be resistant to EGFR inhibitors. Here, Certis reports Whole Genome Sequencing (WGS) of ctDNA from PDX for the monitoring of therapeutic response and demonstrates measurable ctDNA changes concordant with therapeutic response. Altogether, the isolation of ctDNA from PDX models is a robust methodology for interrogating therapeutic efficacy, response and resistance in a preclinical setting that can be translated as a viable biomarker for non-invasive monitoring in patients.\u202f\u202f<\/p>\n\n\n\nFor more information, <a href=\"https:\/\/info.certisoncology.com\/certis-aacr-posters-2023\">visit us<\/a>.<\/p>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong> Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Solutions Announces Three Abstracts Accepted For Presentation at AACR Annual Meeting","post_excerpt":"Certis Oncology Solutions (\u201cCertis\u201d), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine, today announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-solutions-announces-three-abstracts-accepted-for-presentation-at-aacr-annual-meeting","to_ping":"","pinged":"","post_modified":"2024-03-27 17:21:22","post_modified_gmt":"2024-03-27 17:21:22","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=7260","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-solutions-announces-three-abstracts-accepted-for-presentation-at-aacr-annual-meeting\/","post_thumbnail":false},{"ID":4781,"post_author":"6","post_date":"December 2, 2022","post_date_gmt":"2022-12-02 17:56:18","post_content":"\nIn this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to modeling relevant clinical scenarios. Attendees will learn how whole-body and focal radiation can be used to mimic clinical scenarios in both in vivo<\/em> and in vitro<\/em> studies. The featured speakers will discuss the importance of choosing the right type of model to support each study\u2019s purpose and reducing variability between in vitro<\/em> and in vivo<\/em> studies by employing matched pairs of patient-derived xenograft (PDX) models and three-dimensional cell cultures derived from them. Attendees will learn about emerging approaches to humanized PDX models to recapitulate the human tumor microenvironment and evaluate immune response.<\/p>\n\n\n\nTo develop the next generation of targeted cancer therapies, researchers need cancer models that can stand in as true proxies for human disease. Traditional research models commonly used in commercial applications have a place in screening and can provide directional information about potential therapeutic responses. However, they do not replicate the heterogenous biology and complex network of dysregulated pathways that characterize real-life human tumors. In fact, most models used in preclinical drug development fail to address the importance of tumor microenvironment, despite its well-established role in druggability and immune response. Translational research in oncology can greatly benefit from improvements to these models.<\/p>\n\n\n\nInnovative approaches to model development can address many shortcomings of legacy models. What\u2019s more, both in vitro<\/em> and in vivo<\/em> test systems can now be customized to account for the myriad of clinical scenarios (prior treatment, radiotherapy, acquired resistance, metastases) that may ultimately determine clinical response to a given experimental therapy.<\/p>\n\n\n\nTranslational research success is largely dependent upon selecting \u2014 or sometimes custom-developing \u2014 the most appropriate preclinical model to assess a candidate\u2019s therapeutic response. During this webinar, the featured speakers will review current literature on cell culture, organoids\/spheroids and various types of in vivo<\/em> mouse models and discuss emerging techniques for developing more clinically relevant models of cancer.<\/p>\n\n\n\nRegister to learn about the innovations in preclinical model development for translational research in oncology.<\/p>\n\n\n\nJoin experts from Certis Oncology Solutions, Jonathan Nakashima, PhD, Chief Scientific Officer; Jantzen Sperry, PhD, Senior Director, Scientific Operations; and Rajeev Shrimali, PhD, Senior Director, Immuno-Oncology R&D, for the <a href=\"https:\/\/xtalks.com\/webinars\/translational-research-in-oncology-innovations-in-model-development\/\" target=\"_blank\" rel=\"noreferrer noopener\">live webinar<\/a> on Wednesday, December 14, 2022, at 2pm EST (11am PST).<\/p>\n\n\n\nFor more information, or to register for this event, visit <a href=\"https:\/\/xtalks.com\/webinars\/translational-research-in-oncology-innovations-in-model-development\/\" target=\"_blank\" rel=\"noreferrer noopener\">Translational Research in Oncology \u2014 Innovations in Model Development<\/a>.<\/p>\n\n\n\nAbout Certis Oncology Solutions <\/strong> <a href=\"https:\/\/www.certisoncology.com\/#drug-development\" target=\"_blank\" rel=\"noreferrer noopener\">Certis Oncology Solutions<\/a> is a life science technology company specializing in <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/custom-model-development\/\" target=\"_blank\" rel=\"noreferrer noopener\">custom cancer model development<\/a>, from advanced cellular and in vivo<\/em> models of recurrence, resistance and metastasis, to rare and humanized mouse models. We are committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies. <\/p>\n\n\n\n<a href=\"https:\/\/www.certisoncology.com\/about-us\/who-we-are\/\" target=\"_blank\" rel=\"noreferrer noopener\">Learn more.<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Translational Research in Oncology \u2014 Innovations in Model Development, Upcoming Webinar Hosted by Xtalks","post_excerpt":"In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to modeling relevant clinical scenarios. <\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"translational-research-in-oncology-innovations-in-model-development-upcoming-webinar-hosted-by-xtalks","to_ping":"","pinged":"","post_modified":"2024-03-27 17:21:39","post_modified_gmt":"2024-03-27 17:21:39","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=4781","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/translational-research-in-oncology-innovations-in-model-development-upcoming-webinar-hosted-by-xtalks\/","post_thumbnail":false},{"ID":4727,"post_author":"6","post_date":"October 5, 2022","post_date_gmt":"2022-10-05 05:00:00","post_content":"\nSan Diego, CA\u2014Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI\u2122. This proprietary, online repository houses deep molecular characterization data for Certis\u2019 expanding bank of patient-derived xenograft (PDX) tumor models and cancer cell lines. With enhanced search features and user interface, BarneyOI gives cancer researchers easy access to the clinically relevant tumor models they need to acquire actionable therapeutic response data from translational studies.<\/p>\n\n\n\n\u201cCertis was founded on and will remain on the cutting edge of translational science,\u201d said Certis Oncology Solutions\u2019 Chief Executive Officer, Peter Ellman. \u201cAn industry-leading cancer model database is a natural complement to the world\u2019s most clinically relevant, richly characterized cancer models.\u201d<\/p>\n\n\n\nBarneyOI is available online and allows cancer researchers to compare more than three million gene expression results to disease-free tissue. Registered users can search hundreds of highly characterized, richly annotated, low-passage, patient-consented, PDX tumor models and cell lines.<\/p>\n\n\n\nHow BarneyOI Got Its Name<\/strong> The new database was named in honor of Barney Berglund, late son of the company\u2019s chairman and the first cancer patient Certis served. \u201cCertis has grown and expanded considerably over the last few years,\u201d said Ellman. \u201cBringing Barney\u2019s memory into our daily conversations is a great way to remind us all why we come to work each day,\u201d said Ellman. \u201cUltimately, everything we do leads back to improving the lives of real people\u2014our children, parents, friends\u2014who are living with cancer.\u201d<\/p>\n\n\n\nAbout Certis Oncology Solutions <\/strong> Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence\u2122 \u2014 highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.<\/p>\n\n\n\n<a href=\"https:\/\/www.certisoncology.com\/about-us\/who-we-are\/\" target=\"_blank\" rel=\"noreferrer noopener\">Learn more.<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King kking@certisoncology.com 573-818-4528<\/p>\n","post_title":"Certis Oncology Releases New Cancer Model Database, BarneyOI\u2122","post_excerpt":"Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI\u2122. This proprietary, online repository houses deep molecular characterization data for Certis\u2019 expanding bank of patient-derived xenograft (PDX) tumor models and cancer cell lines.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-releases-new-cancer-model-database-barneyoi","to_ping":"","pinged":"","post_modified":"2024-03-27 17:21:51","post_modified_gmt":"2024-03-27 17:21:51","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=4727","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-releases-new-cancer-model-database-barneyoi\/","post_thumbnail":false},{"ID":4536,"post_author":"6","post_date":"June 29, 2022","post_date_gmt":"2022-06-29 22:50:58","post_content":"\nCertis Oncology Solutions, a precision oncology and translational science company, announced that it has been awarded accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care International\u202f(AAALAC International). This voluntary and internationally recognized accreditation reflects the company\u2019s commitment to go beyond standards required by regulatory agencies to achieve excellence in animal care and use.<\/p>\n\n\n\n\u201cThis is another important milestone for Certis, said CEO, Peter Ellman. \u201cSecuring AAALAC accreditation signals to pharmaceutical clients that we are a mature partner with robust and scalable quality systems, and that we are committed to animal use best practices.\u201d<\/p>\n\n\n\nCertis provides high-precision translational <a href=\"https:\/\/www.certisoncology.com\/for-drug-developers\/\">drug discovery and development services<\/a> to therapeutics innovators. Since the launch of its pharmaceutical services offering 18 months ago, the company has partnered with more than 50 oncology-focused drug developers. Unlike most preclinical contract research organizations (CROs), Certis has a precision medicine focus, and also has received CLIA certification from the Centers for Medicare & Medicaid Services\u2014an accreditation that enables the company to accept human biological specimens for diagnostic testing.<\/p>\n\n\n\n\u201cOur direct connection to the clinic is an important differentiator for Certis,\u201d said Ellman. \u201cIt not only allows us to provide <a href=\"https:\/\/www.certisoncology.com\/for-patients\/\">functional precision oncology<\/a> directly to patients, our CLIA status facilitates the conduct of co-clinical trials, which employ mouse avatars of patients enrolled in trials to expedite clinical development.\u201d<\/p>\n\n\n\nTo receive AAALAC International accreditation, an institution must submit a detailed program description that details all aspects of its animal care and use. Once the program description is reviewed, AAALAC International conducts a comprehensive, onsite assessment of the program and facilities to determine if the institution will be awarded accreditation.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n","post_title":"Certis Oncology Awarded AAALAC Accreditation","post_excerpt":"Certis Oncology Solutions, a precision oncology and translational science company, announced that it has been awarded accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care International\u202f(AAALAC International).<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-awarded-aaalac-accreditation","to_ping":"","pinged":"","post_modified":"2024-03-27 17:22:38","post_modified_gmt":"2024-03-27 17:22:38","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=4536","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-awarded-aaalac-accreditation\/","post_thumbnail":false},{"ID":3917,"post_author":"6","post_date":"February 3, 2022","post_date_gmt":"2022-02-03 18:02:18","post_content":"\nCertis Oncology Solutions, Inc. has obtained <a href=\"https:\/\/olaw.nih.gov\/assured\/app\/index.html\" target=\"_blank\" rel=\"noreferrer noopener\">OLAW assurance<\/a>. Insurance ID: D22-01133. <\/p>\n\n\n\n<div class=\"wp-block-media-text alignwide is-stacked-on-mobile\"><figure class=\"wp-block-media-text__media\"><img src=\"https:\/\/www.certisoncology.com\/wp-content\/uploads\/Certis-OLAW-assured-letter-thumbnail.png\" alt=\"Certis Oncology OLAW Assured\" class=\"wp-image-3912 size-full\"\/><\/figure><div class=\"wp-block-media-text__content\">\n<\/p>\n<\/div><\/div>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n","post_title":"Certis Oncology is OLAW Assured","post_excerpt":"Certis Oncology Solutions, Inc. has obtained OLAW assurance. Insurance ID: D22-01133. <\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-is-olaw-assured","to_ping":"","pinged":"","post_modified":"2024-03-27 17:22:48","post_modified_gmt":"2024-03-27 17:22:48","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=3917","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-is-olaw-assured\/","post_thumbnail":false},{"ID":3713,"post_author":"6","post_date":"December 20, 2021","post_date_gmt":"2021-12-20 19:56:00","post_content":"\nCertis Oncology Solutions, a precision oncology and translational science company, announced today the favorable conclusion to legal action brought by AntiCancer, Inc., represented by its CEO and owner, Robert Hoffman. Following a trial, the San Diego Superior Court, presided over by Judge Kenneth Medel, ruled in favor of Certis on all counts, citing Hoffman\u2019s multiple misrepresentations and concealment of important financial facts as evidence of fraud. The court awarded Certis, the cross-complainant, compensatory damages of $625,000 plus another $168,400 related to a February 26, 2021, adjudication of a separate breach-of-contract claim. \u201cDr. Hoffman\u2019s claims were baseless and false, and the courts\u2014once again\u2014have ruled accordingly,\u201d said Certis CEO, Peter Ellman. AntiCancer, Inc., which has been involved in <a href=\"https:\/\/casetext.com\/search?q=patent%20infringement%20anticancer,%20inc.&PHONE_NUMBER_GROUP=P&sort=relevance&p=1&type=case\" target=\"_blank\" rel=\"noreferrer noopener\">numerous lawsuits<\/a> with multiple companies over the last two decades, first filed claims against Certis in 2018, several months after Certis terminated a service agreement and a separate license agreement for cause. The claims most recently adjudicated by the bench trial involved ownership of company assets and payment for scientific services which AntiCancer and Hoffman alleged to have provided. Although most of AntiCancer\u2019s complaints were dismissed in court rulings in 2018-2019, the company issued news releases misrepresenting past court decisions and published defamatory untruths about Certis executives online\u2014a fact underscored by the Superior Court in its recent ruling. The court\u2019s decision states, \u201cDr. Hoffman has done all in his power to damage the reputation of Certis by\u2026continuing to post spurious disparaging comments on his AntiCancer website.\u201d That false information was finally removed from anticancer.com earlier this month, following the court\u2019s ruling received November 30, 2021. \u201cI sincerely hope this will end Dr. Hoffman\u2019s persistent attempts to enrich AntiCancer and himself by discrediting our company and its leaders. Our energies should be directed toward the important work of fighting cancer,\u201d said Ellman. Hoffman\u2019s original complaints were filed and dismissed by the federal court in 2018. Hoffman then issued a news release in November 2018 claiming that ruling was a victory. Following amendment of those complaints, AntiCancer\u2019s claims were again dismissed in federal court and AntiCancer was ordered to pay costs incurred by Certis. AntiCancer subsequently filed additional complaints in San Diego Superior Court, including claims which AntiCancer and Hoffman then lost in summary adjudication in February 2021. The remaining claims adjudicated by the bench trial involved ownership of company assets and claims for payment for scientific services Hoffman alleged that AntiCancer had provided while Hoffman was serving as a board member. In this most recent action in state court, Certis filed a cross complaint against AntiCancer and Hoffman for breach of fiduciary duty and fraud. The court found in favor of Certis and Ellman and against Hoffman and AntiCancer on all claims presented in the trial. Ellman stated that, with additional costs to be assessed, the total judgment in favor of Certis is expected to be well in excess of $800,000. <\/p>\n\n\n\n<a href=\"https:\/\/roa.sdcourt.ca.gov\/roa\/\" target=\"_blank\" rel=\"noreferrer noopener\">Official Court Records<\/a>: CASE NO: 37-2019-00011336-CU-BC-CTL CASE INIT.DATE: 03\/01\/2019<\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n","post_title":"Certis Oncology Prevails in Spurious Lawsuit, Plaintiffs Ordered to Pay Compensatory Damages","post_excerpt":"Certis Oncology Solutions, a precision oncology and translational science company, announced today the favorable conclusion to legal action brought by AntiCancer, Inc., represented by its CEO and owner, Robert Hoffman. <\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-prevails-in-spurious-lawsuit-plaintiff-ordered-to-pay-compensatory-damages","to_ping":"","pinged":"","post_modified":"2024-03-27 17:23:02","post_modified_gmt":"2024-03-27 17:23:02","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=3713","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-prevails-in-spurious-lawsuit-plaintiff-ordered-to-pay-compensatory-damages\/","post_thumbnail":false},{"ID":3212,"post_author":"6","post_date":"July 27, 2021","post_date_gmt":"2021-07-27 23:21:40","post_content":"San Diego-based preclinical translational science company is making moves. Certis Oncology Solutions, Inc., a precision oncology and translational science company, has expanded its operations and moved to a new facility at 5626 Oberlin Drive in San Diego. The new location provides four times the capacity for in vivo efficacy testing and doubles the laboratory space needed to accommodate the company\u2019s growing pharmaceutical services business.<\/p>\n\u201cThe energy and enthusiasm are quite palpable around here,\u201d said Peter Ellman, CEO. \u201cI couldn\u2019t be prouder of our team or more excited about our company\u2019s future.\u201d<\/p>\nCertis was founded in 2016 to provide in vivo drug efficacy testing to individual cancer patients and preclinical services to the life sciences industry in its development of new cancer therapies. The company develops orthotopic patient-derived xenograft (O-PDX) models of human cancers in immunocompromised mice, which function as avatars for individual patients. These avatars enable the simultaneous testing of multiple therapies in the laboratory to determine which treatment or combination of treatments works best\u2014or very importantly, does not work\u2014on an individual patient\u2019s unique form of cancer. Drug innovators contract this same technology to Certis to test and select the most promising candidates for clinical development.<\/p>\n\u201cEvery day, we learn more about the biology, chemistry and complex mechanisms that drive cancer. At Certis, we\u2019re committed to staying on the leading edge of oncological science, leveraging the most clinically relevant models, cutting edge analytical techniques and advanced instrumentation to bring greater certainty to the fight against cancer,\u201d said Ellman.<\/p>\nCertis will host an open house on July 30 to celebrate and showcase its new capabilities to the local medical, pharmaceutical and life sciences communities.<\/p>\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n","post_title":"A Growing Certis Oncology Solutions Expands Laboratory Footprint and Capabilities","post_excerpt":"San Diego-based preclinical translational science company is making moves. \nCertis Oncology Solutions, Inc., a precision oncology and translational science company, has expanded its operations and moved to a new facility at 5626 Oberlin Drive in San Diego.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-solutions-expands-laboratory-footprint-and-capabilities","to_ping":"","pinged":"","post_modified":"2024-03-27 17:23:15","post_modified_gmt":"2024-03-27 17:23:15","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=3212","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-solutions-expands-laboratory-footprint-and-capabilities\/","post_thumbnail":false},{"ID":2339,"post_author":"6","post_date":"January 5, 2021","post_date_gmt":"2021-01-05 22:49:46","post_content":"\nCertis Oncology Solutions, a precision oncology and translational sciences company, announced it will make available its personalized approach to drug efficacy testing to the commercial pharmaceutical industry. Industry veteran Debbie Snyder-Stanton has joined the company as Vice President, Pharmaceutical Business Development.<\/p>\n\n\n\n\u201cMore than half of all new cancer drugs fail in clinical trials due to problems with efficacy,\u201d said Peter Ellman, Certis Oncology CEO. \u201cCertis will leverage our success using orthotopic patient-derived xenograft (O-PDX) models in precision oncology to offer industry a better choice for translational drug development,\u201d he said. \u201cWhile this approach takes specialized scientific expertise, no other modality offers greater certainty of tumor response than this type of in vivo<\/em> testing.\u201d<\/p>\n\n\n\nThe Certis approach is rooted in a technology rapidly gaining prominence in basic research: orthotopic patient derived xenograft (O-PDX) models. By surgically engrafting a small tissue specimen of a patient\u2019s tumor into the anatomically correct place in immunocompromised mice, scientists create mouse \u201cavatars\u201d of the patient\u2019s cancer. The resulting O-PDX models enable simultaneous, in vivo<\/em> functional assays of multiple therapeutic options in the laboratory. A large body of academic literature demonstrates superior concordance between orthotopic models and human subjects when compared to the subcutaneous and cell-derived PDX models that are more commonly used in commercial drug development. The modality also can be employed in mouse\u2013human co-clinical trials, in which an experimental therapy is simultaneously tested in clinical trial participants and mouse models derived from tumors of those same patients. While not yet widely adopted by industry, co-clinical trials represent a promising opportunity for developing new combination treatments, identifying predictive biomarkers and providing insights into acquired cancer drug resistance.<\/p>\n\n\n\nDebbie Snyder-Stanton is the newest member of the Certis executive team. A contract research organization (CRO) industry veteran, Debbie has more than 20 years\u2019 experience in business development, operations, product management and marketing in the oncology field. She started her career as a laboratory scientist at the British Columbia BC Cancer Terry Fox Lab before helping to grow four successful startup companies: StemCell Technologies, VSM MedTech, TD2 and Crown Biosciences. Prior to joining Certis, Debbie held positions as Executive Director, Business Development of Crown Bioscience Inc, and Vice President of Business Development at TGen\u2019s Translational Drug Development (TD2). She earned her M.B.A at Simon Fraser University, and a Medical Laboratory Science Degree at the University of Manitoba, Red River Community College.<\/p>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n","post_title":"Certis Oncology Offers Translational Science Services to Pharmaceutical Industry, Welcomes New Business Development Leader","post_excerpt":"Certis Oncology Solutions, a precision oncology and translational sciences company, announced it will make available its personalized approach to drug efficacy testing to the commercial pharmaceutical industry. Industry veteran Debbie Snyder-Stanton has joined the company as Vice President, Pharmaceutical Business Development.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-oncology-offers-translational-science-services","to_ping":"","pinged":"","post_modified":"2024-03-19 20:06:24","post_modified_gmt":"2024-03-19 20:06:24","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=2339","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-oncology-offers-translational-science-services\/","post_thumbnail":false},{"ID":2127,"post_author":"6","post_date":"December 3, 2020","post_date_gmt":"2020-12-03 17:53:45","post_content":"\n\u201cThe best way to get everyone back to living a full life \u2014 including enjoying live performances \u2014 is through more and more accurate testing,\u201d Peter Ellman, CEO of Certis Oncology Solutions, said in a statement. \u201cWe applaud Mainly Mozart for finding creative ways to bring people together and are sincerely pleased to play this role in ensuring the musicians\u2019 safety.\u201d <a rel=\"noreferrer noopener\" href=\"https:\/\/www.sandiegouniontribune.com\/entertainment\/classical-music\/story\/2020-10-16\/what-do-you-do-before-mounting-one-of-the-first-u-s-orchestral-concerts-during-a-pandemic-you-test-all-the-musicians-for-covid-19\" target=\"_blank\">Get the full story<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n\n\n\n<\/p>\n","post_title":"Certis Teams Up with Mainly Mozart to Keep the Music Playing","post_excerpt":"\u201cThe best way to get everyone back to living a full life \u2014 including enjoying live performances \u2014 is through more and more accurate testing,\u201d Peter Ellman, CEO of Certis Oncology Solutions, said in a statement. \u201cWe applaud Mainly Mozart for finding creative ways to bring people together and are sincerely pleased to play this role in ensuring the musicians\u2019 safety.\u201d<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"certis-teams-up-with-mainly-mozart-to-keep-the-music-playing","to_ping":"","pinged":"","post_modified":"2024-03-25 19:12:39","post_modified_gmt":"2024-03-25 19:12:39","post_content_filtered":"","post_parent":0,"guid":"https:\/\/www.certisoncology.com\/?post_type=type-news&p=2127","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/certis-teams-up-with-mainly-mozart-to-keep-the-music-playing\/","post_thumbnail":false},{"ID":1284,"post_author":"6","post_date":"July 9, 2020","post_date_gmt":"2020-07-09 19:05:00","post_content":"\nSan Diego, CA<\/strong>--Certis Oncology Solutions, a clinical research organization (CRO) and precision cancer therapy company, announced today it is offering mobile COVID-19 testing services to area businesses.<\/p>\n\n\n\n\u201cWe felt compelled to pitch in,\u201d said Peter Ellman, CEO. \u201cAs businesses reopen, employers are concerned about the ongoing safety of employees and clientele. Regular testing can identify those with active coronavirus infections\u2014people who are contagious, but who may be asymptomatic. That\u2019s how we will help reduce transmission rates, which is key to getting this disease under control.\u201d<\/p>\n\n\n\nCertis Oncology Solutions is one of few area laboratories licensed by the California Department of Public Health and Centers for Medicare and Medicaid Services, and is CLIA-certified for high complexity testing\u2014a requirement for compliance with California and U.S. clinical laboratory laws. That certification, in combination with Certis\u2019 in-house molecular biologists and advanced analytical instrumentation, enabled Certis to quickly pivot in response to the COVID-19 pandemic. The company will offer an FDA-approved viral test, which employs nasopharyngeal swabbing and Reverse Transcription Polymerase Chain Reaction (RT-PCR) analyses\u2014widely considered to be the gold standard in biological identification.<\/p>\n\n\n\nCertis will bring testing to individual work sites\u2014minimizing exposure risk and reducing employees\u2019 time away from work. Nasopharyngeal swabbing is performed by Licensed Practice Nurses (LPNs), and samples are analyzed in Certis\u2019 Sorrento Valley-based laboratory. The company aims to deliver results in 24-48 hours. For more information, visit <a href=\"https:\/\/www.certisoncology.com\/covid-19-workplace-testing\/\">certisoncology.com<\/a>.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\nABOUT CERTIS ONCOLOGY SOLUTIONS<\/strong><\/p>\n\n\n\nCertis Oncology Solutions was formed in 2016 with the mission to provide individualized treatment options to cancer patients. Our technology enables oncologists to determine with precision the most effective available therapies to treat each patient\u2019s unique disease. Pharmaceutical companies leverage our expertise in precision oncology to obtain accurate, scientifically relevant data for preclinical decision-making. Findings from our science can dramatically improve lead optimization of new drug candidates, reduce development risk, and expedite path to clinical trials. For more information, visit <\/strong><a href=\"https:\/\/www.certisoncology.com\/covid-19-workplace-testing\/\">certisoncology.com<\/strong><\/a>.<\/strong><\/p>\n\n\n\n###<\/p>\n\n\n\n<hr class=\"wp-block-separator has-css-opacity\"\/>\n\n\n\nMEDIA CONTACT Certis Oncology Solutions Kristein King <a href=\"mailto:kking@certisoncology.com\">kking@certisoncology.com<\/a> 573-818-4528<\/p>\n","post_title":"Certis Oncology Solutions Announces Mobile COVID-19 Testing","post_excerpt":"Certis Oncology Solutions, a clinical research organization (CRO) and precision cancer therapy company, announced today it is offering mobile COVID-19 testing services to area businesses.<\/p>\n","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"announces-mobile-covid-19-testing","to_ping":"","pinged":"","post_modified":"2024-03-25 19:14:20","post_modified_gmt":"2024-03-25 19:14:20","post_content_filtered":"","post_parent":0,"guid":"http:\/\/certisoncology.com\/?post_type=type-news-blog&p=1284","menu_order":0,"post_type":"type-news","post_mime_type":"","comment_count":"0","filter":"raw","permalink":"https:\/\/www.certisoncology.com\/news\/announces-mobile-covid-19-testing\/","post_thumbnail":false}]}"></component-5f8f6262a8d2a><component-5f6e47dd83dfe :arr="{"headline":"PRESS INQUIRIES","content":"","card":"<h3>PLEASE CONTACT<\/h3>\nCertis Oncology Solutions \nKristein King \n<a href=\"mailto:kking@certisoncology.com\" target=\"_blank\" rel=\"noopener\">kking@certisoncology.com<\/a> \n573-818-4528<\/p>\n","map":{"lat":"32.890679","lng":"-117.199536","location":"Certis Oncology Solutions, Inc"}}"></component-5f6e47dd83dfe> </div> <footer> <div class="container"> <div class="d-flex flex-wrap flex-md-nowrap"> <div class="mb-4 mb-md-2 mb-lg-0 mr-sm-4"> <figure class="mb-3 mr-lg-6"> <img class="img-fluid d-block" src="/wp-content/themes/certis/images/certis-logo-lockup-white.svg"> </figure> <address> <div> 5626 Oberlin Drive, Suite 110 San Diego, CA 92121 </div> <div> Drug Development: 858-988-1033 Patients & Oncologists: 858-228-4110 Main: 858-952-1820 </div> </address> </div> <nav class="flex-grow-1"> <ul class="sections ml-0 ml-md-4"> <li> <h4 style="text-transform: uppercase;">Drug Developers</h4> <ul class="child-pages"> <li><a href="https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/">CertisAI™</a></li> <li><a href="https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/">Cancer Models</a></li> <li><a href="https://www.certisoncology.com/for-drug-developers/custom-model-development/">Custom Model Development</a></li> <li><a href="https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/">In Vitro/Ex Vivo Pharmacology</a></li> <li><a href="https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/">In Vivo Pharmacology</a></li> <li><a href="https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/">Imaging/Endpoint Analysis</a></li> <li><a href="https://www.certisoncology.com/for-drug-developers/immuno-oncology/">Immuno-Oncology</a></li> </ul> </li> <li> <h4 style="text-transform: uppercase;">Oncologists</h4> <ul class="child-pages"> <li><a href="https://www.certisoncology.com/for-oncologists/order-yourpdx/">Order YourPDX®</a></li> <li><a href="https://www.certisoncology.com/for-oncologists/clinical-research/">Clinical Research</a></li> <li><a href="https://www.certisoncology.com/for-oncologists/patient-education/">Patient Education</a></li> </ul> </li> <li> <h4 style="text-transform: uppercase;">Resource Library</h4> <ul class="child-pages"> <li><a href="https://www.certisoncology.com/resources/cancer-market-facts/">Cancer Facts</a></li> <li><a href="https://www.certisoncology.com/resources/clinical-results/">Clinical Results</a></li> <li><a href="https://www.certisoncology.com/resources/supporting-research/">Supporting Research</a></li> <li><a href="https://www.certisoncology.com/resources/media/">Media</a></li> <li><a href="https://whitepapers.certisoncology.com/">White Papers</a></li> </ul> </li> <li> <h4 style="text-transform: uppercase;">About</h4> <ul class="child-pages"> <li><a href="https://www.certisoncology.com/about-us/mission-vision-values/">Mission, Vision & Values</a></li> <li><a href="https://www.certisoncology.com/about-us/our-team/">Team</a></li> <li><a href="https://www.certisoncology.com/about-us/our-story/">Our Story</a></li> <li><a href="https://www.certisoncology.com/about-us/careers/">Careers</a></li> <li><a href="https://www.certisoncology.com/about-us/news/">Company News</a></li> <li><a href="https://www.certisoncology.com/contact-us/">Contact Us</a></li> <li><a href="https://oncointel.certisoncology.com/">Login</a></li> <li><a href="https://www.certisoncology.com/privacy-policy/">Privacy Policy</a></li> </ul> </li> </ul> </nav> </div> <div class="d-flex justify-content-between align-items-end mt-2"> <div class="social-media icons"> <ul> <li><a href="https://www.facebook.com/CertisOncology" target="_blank" class="facebook"></a></li> <li><a href="https://www.linkedin.com/company/certis-oncology" target="_blank" class="linkedin"></a></li> <li><a href="https://twitter.com/CertisOncology" target="_blank" class="twitter"></a></li> <li><a href="https://www.instagram.com/certis_oncology" target="_blank" class="instagram"></a></li> <li><a href="https://www.youtube.com/channel/UCeX4_jh3RlNKxQxZ89_utjg" target="_blank" class="youtube"></a></li> <li><a href="https://blog.certisoncology.com/" target="_blank" class="blog"></a></li> </ul> </div> <div class="d-flex justify-content-end"> <figure class="mouse mx-auto"> <img class="img-fluid d-block" src="/wp-content/themes/certis/images/certis-footer-mouse.svg"> </figure> </div> </div> <hr /> <div class="row"> <div class="col"> <div class="copyright mb-2 mb-sm-0"> ©2024 Certis Oncology Solutions. All rights reserved. Testimonials appearing on this site reflect real-life experiences of those who have used our services. To protect their privacy, photos feature models. </div> </div> </div> </div> </footer> <cookie-consent :content=""We may use \u201ccookies,\u201d log files, clear gifs or other technologies to help personalize your online experience. For example, a cookie can help us to recall your specific information on subsequent visits. Other technologies allow us to determine which email subscribers click through and read our newsletters. For more information see our <a href=\"\/privacy-policy\/\">Privacy Policy and <\/a><a href=\"\/privacy-policy\/#cookie-statement\">Cookie Statement<\/a><a href=\"\/privacy-policy\/\">.<\/a><\/p>\n""></cookie-consent> </div>  <script crossorigin="anonymous" src="https://polyfill.io/v3/polyfill.min.js?features=es6%2Ces5%2CURL%2Ces7"></script> <script src="https://maps.googleapis.com/maps/api/js?key=AIzaSyCO3sLhHX6ZWiN5jQAYrGQk_7nXYBhBJac"></script> <script src="/wp-content/themes/certis/dist/js/app.js?v2"></script> </body> </html>

CINXE.COM

Company News - Certis Oncology